Loading…
Chronic Kidney Disease Improvement in Research and Treatment Act of 2015
Legislative Progress
Introduced
February 26, 2015
Latest Action
February 26, 2015
Primary Sponsor
Benjamin L. CardinDemocratic(MD)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,548 other S bills in the 114th — cohort avg 43d
Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 Amends title XVIII (Medicare) of the Social Security Act to revise Medicare payments for dialysis services provided to individuals with end stage renal disease (ESRD) and acute kidney injury. Makes individuals with ESRD eligible for Medicare Advantage. Allows dialysis facilities to provide kidney disease education services and allows physician assistants, nurse practitioners, or clinical nurse specialists to refer individuals to those services. Requires the Department of Health and Human Services (HHS) to establish an ESRD Care Coordination program to provide higher Medicare payments to nephrologists, dialysis facilities, and other providers that reduce spending on ESRD by being part of a coordinated care organization. Amends the Public Health Service Act to include dialysis as a service provided by the National Health Service Corps in health professional shortage areas. Makes nephrologists and non-physician practitioners who provide dialysis eligible for the National Health Service Corps Scholarship Program and Loan Repayment Program. Requires the Government Accountability Office to submit a report identifying gaps in chronic kidney disease research and comparing research funding to expenditures on disease treatment. Requires HHS to report on: (1) the causes of kidney disease and efforts to treat kidney disease in disproportionately affected minority populations, and (2) disincentives in Medicare payment systems that create barriers to kidney transplants and post-transplant care for beneficiaries with ESRD.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (16)
Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S1166; text of measure as introduced: CR S1166-1168)
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2018 · second_quarter · Medicare/Medicaid
S. 598 / H.R. 1130, "Chronic Kidney Disease Improvement in Research and Treatment Act of 2015", regarding all provisions. S. 870, "Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017", regarding all provisions. H.R. 3178, "Medicare Part B Improvement Act of 2017", regarding all provisions.
Client expense: $900,000 · Firm income: Not reported
Government targets: Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE
2018 · first_quarter · Medicare/Medicaid
S. 598 / H.R. 1130, "Chronic Kidney Disease Improvement in Research and Treatment Act of 2015", regarding all provisions. S. 870, "Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017", regarding all provisions. H.R. 3178, "Medicare Part B Improvement Act of 2017", regarding all provisions.
Client expense: $570,000 · Firm income: Not reported
Government targets: Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE
2017 · fourth_quarter · Medicare/Medicaid
S. 598 / H.R. 1130, "Chronic Kidney Disease Improvement in Research and Treatment Act of 2015", regarding all provisions. S. 870, "Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017", regarding all provisions. H.R. 3178, "Medicare Part B Improvement Act of 2017", regarding all provisions.
Client expense: $570,000 · Firm income: Not reported
Government targets: Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE
2017 · third_quarter · Medicare/Medicaid
S. 598 / H.R. 1130, "Chronic Kidney Disease Improvement in Research and Treatment Act of 2015", regarding all provisions. S. 870, "Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017", regarding all provisions. H.R. 3178, "Medicare Part B Improvement Act of 2017", regarding all provisions.
Client expense: $430,000 · Firm income: Not reported
Government targets: Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE
2017 · second_quarter · Medicare/Medicaid
S. 598 / H.R. 1130, "Chronic Kidney Disease Improvement in Research and Treatment Act of 2015", regarding all provisions. S. 3504, "Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2016", regarding all provisions.
Client expense: $670,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Republican |
| LA |
| Debbie Stabenow | Democratic | MI |
| Gary C. Peters | Democratic | MI |
| Kirsten E. Gillibrand | Democratic | NY |
| Michael F. Bennet | Democratic | CO |
| Mike Crapo | Republican | ID |
| Robert P. Casey, Jr. | Democratic | PA |
2017 · second_quarter · Health Issues
Implementation of the Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); The Medicare Access and CHIP Reauthorization Act of 2015 (H.R. 1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The ERSD Choice Act (H.R. 5659); Issues related to ERSD Program; S. 598 and H.R. 1130, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Medicare Advantage; Senate Finance Committee Chronic Care Working Group; Integrated care legislation; Access to coverage in Health Insurance Marketplaces for ESRD; Implementation of Pub. L. 114-27, the Trade Preferences Extension Act of 2015; OCR anti-discrimination proposed and final rules; ERSD quality programs; ERSD payment rules; ESRD prospective payment system CY 2017; Quality Incentive Program PY 2020 Final Rule
Client expense: $140,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2017 · second_quarter · Medicare/Medicaid
Implementation of the Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); The Medicare Access and CHIP Reauthorization Act of 2015 (H.R. 1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The ERSD Choice Act (H.R. 5659); Issues related to ERSD Program; S. 598 and H.R. 1130, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Medicare Advantage; Senate Finance Committee Chronic Care Working Group; Integrated care legislation; Access to coverage in Health Insurance Marketplaces for ESRD; Implementation of Pub. L. 114-27, the Trade Preferences Extension Act of 2015; OCR anti-discrimination proposed and final rules; ERSD quality programs; ERSD payment rules; ESRD prospective payment system CY 2017; Quality Incentive Program PY 2020 Final Rule
Client expense: $140,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2017 · first_quarter · Medicare/Medicaid
Raise awareness with legislators about the barriers to and the importance of protecting access for home dialysis. S. 598 / H.R. 1130, "Chronic Kidney Disease Improvement in Research and Treatment Act of 2015", regarding all provisions. H.R. 2948, "Medicare Tele-health Parity Act of 2015", regarding all provisions. S. 2484, "CONNECT for Health Act", regarding all provisions. S. 3504, "Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2016", regarding all provisions. Medicare ESRD reimbursement for hemodialysis.
Client expense: $500,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · first_quarter · Medicare/Medicaid
Implementation of the Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); The Medicare Access and CHIP Reauthorization Act of 2015 (H.R. 1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The ERSD Choice Act (H.R. 5659); Issues related to ERSD Program; S. 598 and H.R. 1130, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Medicare Advantage; Senate Finance Committee Chronic Care Working Group; Integrated care legislation; Access to coverage in Health Insurance Marketplaces for ESRD; Implementation of Pub. L. 114-27, the Trade Preferences Extension Act of 2015; OCR anti-discrimination proposed and final rules; ERSD quality programs; ERSD payment rules.
Client expense: $230,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2017 · first_quarter · Health Issues
Implementation of the Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); The Medicare Access and CHIP Reauthorization Act of 2015 (H.R. 1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The ERSD Choice Act (H.R. 5659); Issues related to ERSD Program; S. 598 and H.R. 1130, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Medicare Advantage; Senate Finance Committee Chronic Care Working Group; Integrated care legislation; Access to coverage in Health Insurance Marketplaces for ESRD; Implementation of Pub. L. 114-27, the Trade Preferences Extension Act of 2015; OCR anti-discrimination proposed and final rules; ERSD quality programs; ERSD payment rules.
Client expense: $230,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medicare/Medicaid
Part D drug coverage and patient access issues and policy ESRD bundling and drug reimbursement issues HCPCS coding and reimbursement decisions Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Least costly alternative (LCA) policy Changes re: Medicare Part B and Average Sales Price Medicare secondary payor for ESRD services Extension of rebates on Medicare Part D drugs Performance measures for bone and mineral metabolism for ESRD program Implementation of American Taxpayer Relief Act of 2012 H.R. 1416, Cancer Patient Protection Act of 2015 21st Century Cures/Innovation initiatives, including H.R. 6, 21st Century Cures Act S. 506, To amend Part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes H.R. 696, To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes Medicaid drug rebate, drug coverage and patient access to therapies issues and policy S. 31, Medicare Prescription Drug Price Negotiation Act of 2015 H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 648, Medicare Formulary Improvement Act of 2015 H.R. 2, Medicare Access and CHIP Reauthorization Act of 2015 H.R.2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015 H.R. 5122, To prohibit further action on the proposed rule regarding testing of Medicare Part B Prescription Drug Models
Client expense: $260,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs, including those contained in S. 122, Safe and Affordable Drugs from Canada Act of 2015 Health technology assessment of orphan drugs Sequestration of FDA user fees H.R. 1376, Patient Choice Act of 2015 H.R. 790, Compassionate Freedom of Choice Act of 2015 H.R. 1600, Patients' Access to Treatments Act of 2015 21st Century Cures/Innovation initiatives including H.R. 6, 21st Century Cures Act and the Innovation for Healthier Americans Initiative, including the following: S. 2055, The Medical Countermeasures Innovation Act of 2015; S. 2512, Adding Zika Virus to the FDA Priority Review Voucher Program Act; S. 2030, The Advancing Targeted Therapies for Rare Diseases Act of 2015; S. 849, Advancing Research for Neurological Diseases Act of 2015; S. 2700, FDA and NIH Workforces Authorities Modernization Act H.R. 909, Andrea Sloan CURE Act S. 1421 and H.R.971, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015 Implementation of the FDA Safety and Innovation Act (FDASIA) (Pub. L. 112-144) Regulation of innovative biological products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development S. 320, Medical Innovation Act H.R. 744, Medical Innovation Act S. 2615, Increasing Competition in Pharmaceuticals Act H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015 H.R. 1531 and S.1878, Advancing Hope Act of 2015 Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period Issues and policies related to biosimilars FDA guidance Issues and policies related to FDA oversight and management Issues and policies related to expanded access programs Issues and policies related to patient involvement with FDA decision making S. 289 and H.R. 2104, American Cures Act Legislation pertaining to FDA priority review vouchers, generally Legislation pertaining to the applicability of the ACA tax carve out for non-orphan drug designated drugs, generally, including H.R. 3678, Preserving Access to Orphan Drugs Act of 2015 H.R. 3618 and S. 1906, Orphan Drug Fairness Act Issues related to the value of prescription medicines, generally, and including S. 2023, Prescription Drug Affordability Act of 2015 Drug shortage issues Issues related to health care transparency S. 2055, Medical Countermeasure Innovation Act of 2016 H.R. 3299, Strengthening Public Health Emergency Response Act S. 2700, FDA and NIH Workforce Authorities Modernization Act S. 2713, Advancing Precision Medicine Act of 2016 S. 2745, Advancing NIH Strategic Planning and Representation in Medical Research Act S. 2742, Promoting Biomedical Research and Public Health for Patients Act S. 3239, H.R. 5858, The RACE for Children Act S. 2689, The REGROW Act S. 1878, Advancing Hope Act of 2016
Client expense: $260,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
Healthcare reform In-home dialysis H.R. 1130/S.598 - The Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 FDA Reform - 21st Century Cures Act Availability of medical products
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Energy/Nuclear
S. 598 - Appliance Standards Improvement Act - Provisions on new product categories, one-watt standby power, new Energy Super Star designation S. 398 - Amendments to Energy Policy and Conservation Act - To improve energy efficiency of certain appliances & equipment S. 2012 - Energy Policy Modernization Act of 2016 - Requirements for energy-efficient and energy-saving information technologies, energy efficient data centers and vehicle research and development - To improve energy efficiency in buildings, appliances, and motor vehicles DOE TV energy use standards and energy consumption test procedures FTC Energy Guide labels; Environmental Marketing Claims/Green Guides EPA-DOE Energy Star specifications development (audio/DVD, TVs, computers, displays, set-top boxes, ventilation fans, luminaries, central air conditioners, residential refrigerators) DOE Appliance energy efficiency standards' development DOE Microwave energy use standards and test procedures (standby- and on-mode power) H.R. 4017 - Smart Energy Act - Provisions to create Federal loan program for energy efficiency upgrades in government, school, and hospital buildings DOE Energy conservation standards for commercial products' compressors DOE Energy conservation standards for split-type air conditioners DOE Energy conservation standards for computers DOE Energy use test procedures for TVs H.R. 2412 - New Energy for America Act - Tax credits for residential systems to enhance energy efficiency
Client expense: $140,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Energy, Dept of, Environmental Protection Agency (EPA), Federal Communications Commission (FCC), Federal Trade Commission (FTC), Federal Transit Administration (FTA), HOUSE OF REPRESENTATIVES, Natl Highway Traffic Safety Administration (NHTSA), Natl Telecommunications & Information Administration (NTIA), SENATE, Transportation, Dept of (DOT)
2016 · fourth_quarter · Medicare/Medicaid
H.R. 34 21st Century Cures Act (Provisions relating to ESRD Choice Act) H.R. 5506/S. 5090 Dialysis PATIENT Demonstration Act (All provisions) H.R. 5659 ESRD Choice Act of 2016 (All provisions) Conditions for Coverage for End-Stage Renal Disease Facilities-Third Party Payment (CMS-3317-IFC) H.R. 270 Flexibility in Health IT Reporting Act (All provisions) S. 598 Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 (All provisions) H.R. 1130 Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 (All provisions) S. 776 Medication Therapy Management Empowerment Act of 2015 (All provisions) H.R. 244 MAC Transparency Act (All provisions) H.R. 2507 The Increasing Regulatory Fairness Act (All provisions) S. 2484 CONNECT for Health Act (All provisions) Comprehensive reforms to meaningful use; stage 3 meaningful use proposed rule CMS regulations pertaining to reimbursement rates for ESRD-related services CMS survey and certification of kidney dialysis centers CMS regulations related to the treatment of Medicare Part C and Part D CMS regulations pertaining to reimbursement rates for ESRD-related services CMS vascular care rate change proposal CMS/Medicare Advantage ESRD rate formulation
Client expense: $720,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
2016 · fourth_quarter · Health Issues
H.R. 34 21st Century Cures Act (Provisions relating to ESRD Choice Act) H.R. 5506/ H.R. 5942/S. 3090 Dialysis PATIENT Demonstration Act of 2016 (All provisions) H.R. 5659 ESRD Choice Act of 2016 (All provisions) Conditions for Coverage for End-Stage Renal Disease Facilities-Third Party Payment (CMS-3317-IFC) H.R. 270 Flexibility in Health IT Reporting Act (All provisions) S. 598 Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 (All provisions) H.R. 1130 Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 (All provisions) S. 776 Medication Therapy Management Empowerment Act of 2015 (All provisions) H.R. 244 MAC Transparency Act (All provisions) H.R. 2507 The Increasing Regulatory Fairness Act (All provisions) S. 2484 CONNECT for Health Act (All provisions) Comprehensive reforms to meaningful use; stage 3 meaningful use proposed rule CMS regulations related to the treatment of Medicare Part C and Part D CMS regulations pertaining to reimbursement rates for ESRD-related services CMS survey and certification of kidney dialysis centers CMS vascular care rate change proposal CMS/Medicare Advantage ESRD rate formulation
Client expense: $720,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
2016 · fourth_quarter · Medicare/Medicaid
Issues related to End Stage Renal Disease (ESRD) program; S. 598/H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Senate Finance Committee's Chronic Care Working Group; H.R. 5659, ESRD Choice Act of 2016
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medicare/Medicaid
Issues related to End Stage Renal Disease (ESRD); S. 598/H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act; Medicare Advantage; Senate Finance Committee's Chronic Care Working Group; Telehealth; H.R. 5659, ESRD Choice Act of 2016
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medicare/Medicaid
Raise awareness with legislators about the barriers to and the importance of protecting access for home dialysis. S. 598 / H.R. 1130, "Chronic Kidney Disease Improvement in Research and Treatment Act of 2015", regarding all provisions. H.R. 2948, "Medicare Tele-health Parity Act of 2015", regarding all provisions. H.R. 5659, "ESRD Choice Act of 2016", regarding all provisions. S. 2484, "CONNECT for Health Act", regarding all provisions. S. 3504, "Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2016", regarding all provisions.
Client expense: $300,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medicare/Medicaid
Implementation of P.L. 111-148 Patient Protection and Affordable Care Act; ESRD PPS and QIP proposed and final rules for CY 2017; physician fee schedule rule for CY 2017; ESRD quality programs; ESRD Five Star initiative; Implementation of P.L. 113-93 Protecting Access to Medicare Act of 2014; HR 1130 Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; S 598 Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Implementation of Pub. L. No. 114-27 (H.R. 1295) Trade Preferences Extension Act of 2015; Senate Chronic Care Work Group; Letter to Issuers; Notice of Benefits and Payment Policy proposed rule; OCR antidiscrimination proposed and final rule; CMS Notice of Benefits and Payment Parameters rules; Medicare MA and Part D Letter to Issues; coordinated care legislation
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, White House Office
2016 · fourth_quarter · Medicare/Medicaid
Implementation of P.L. 111-148 Patient Protection and Affordable Care Act; ESRD PPS and QIP rules; physician fee schedule proposed and final rule; ESRD quality programs; ESRD Five Star initiative; Implementation of P.L. 113-93 Protecting Access to Medicare Act of 2014; H.R. 1130 and S. 598 Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Implementation of Pub. L. No. 114-27 (H.R. 1295) Trade Preferences Extension Act of 2015; OCR antidiscrimination proposed and final rule; CMS Notice of Benefits and Payment Parameters final rule
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Medicare and Medicaid Services (CMS)
2016 · fourth_quarter · Health Issues
Implementation of Patient Protection and Affordable Care Act (including comments on inappropriate steering of individuals eligible for Medicare and Medicaid benefits to individual Marketplace plans) Initiatives to increase and facilitate organ transplantation,including S. 2584 and H.R. 4616, Living Donor Protection Act S. 598 and H.R. 1130, Chronic Kidney Disease Improvement in Research and Training Act Patient Access to drug therapies Initiatives to support early detection and management of Chronic Kidney Disease Insurance discrimination and Third Party Premium Assistance
Client expense: $65,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, Veterans Affairs, Dept of (VA), White House Office
2016 · fourth_quarter · Medical/Disease Research/Clinical Labs
The Chronic Kidney Disease Improvement in Research and Treatment Act S.598 H.R.1130.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
Implementation of the Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); The Medicare Access and CHIP Reauthorization Act of 2015 (H.R. 1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The ERSD Choice Act (H.R. 5659); Issues related to ERSD Program; S. 598 and H.R. 1130, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Medicare Advantage; Senate Finance Committee Chronic Care Working Group; Integrated care legislation; Access to coverage in Health Insurance Marketplaces for ESRD; Implementation of Pub. L. 114-27, the Trade Preferences Extension Act of 2015; OCR anti-discrimination proposed and final rules; ERSD quality programs; ERSD payment rules.
Client expense: $270,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medicare/Medicaid
Implementation of the Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); The Medicare Access and CHIP Reauthorization Act of 2015 (H.R. 1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The ERSD Choice Act (H.R. 5659); Issues related to ERSD Program; S. 598 and H.R. 1130, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Medicare Advantage; Senate Finance Committee Chronic Care Working Group; Integrated care legislation; Access to coverage in Health Insurance Marketplaces for ESRD; Implementation of Pub. L. 114-27, the Trade Preferences Extension Act of 2015; OCR anti-discrimination proposed and final rules; ERSD quality programs; ERSD payment rules.
Client expense: $270,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
Supported legislation to permit patients with ESRD enrolling in Medicare Advantage Plans (H.R. 5659) Supported legislation to expand telehealth access S.2484 (CONNECT Act) Supported HR1130/S598 (comprehensive kidney care legislation)
Client expense: $40,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, Veterans Affairs, Dept of (VA), White House Office
2016 · fourth_quarter · Medicare/Medicaid
Urge Congress to open Medicare Advantage to dialysis patients (HR 5659); Support ESRD care coordination legislation - the Dialysis PATIENTS Act (HR 5506/S 3090); Encourage support for to improve kidney disease research and treatment (HR 1130/S 598); Protect Medicare funding for dialysis patients; Improve access to home dialysis treatment; and Ensure ESRD patients retain access to commercial insurance.
Client expense: $50,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medicare/Medicaid
S. 3504 - Creating High Quality Results and Outcome Necessary to Improve Chronic Care Act of 2016 - Issues related to ESRD, palliative care, telemedicine and other issues related to better serving Medicare beneficiaries with End Stage Renal Disease. H.R.1130/S.598 - Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 - Issues related to giving ESRD patients greater choice in their Medicare coverage. H.R.5506/S. 3090 - Dialysis PATIENT Demonstration Act - legislation to create a comprehensive care model for individuals living with End Stage Renal Disease. Work on current and potential demonstration projects in Medicare to support better integration of care for ESRD patients with both CMS and Members of Congress. Issues focused on ESRD and Risk Adjustment for chronically ill patients and related work being conducted by the Senate Finance Committee. Legislative and Administrative actions related to factoring in Socio Economic Status into policies impacting all beneficiaries and their providers.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
S. 3504 - Creating High Quality Results and Outcome Necessary to Improve Chronic Care Act of 2016 - Issues related to ESRD, palliative care, telemedicine and other issues related to better serving Medicare beneficiaries with End Stage Renal Disease. H.R.1130/S.598 - Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 - Issues related to giving ESRD patients greater choice in their Medicare coverage. H.R.5506/S. 3090 - Dialysis PATIENT Demonstration Act - legislation to create a comprehensive care model for individuals living with End Stage Renal Disease. Work on current and potential demonstration projects in Medicare to support better integration of care for ESRD patients with both CMS and Members of Congress. Issues focused on ESRD and Risk Adjustment for chronically ill patients and related work being conducted by the Senate Finance Committee. CMS policies related to Medicare Advantage with specific focus on the formula asserted for the Medicare Advantage Risk Adjustment factor and its impact on beneficiaries, plans and providers who serve Medicare Beneficiaries who live with multiple chronic conditions. Legislative and Administrative actions related to factoring in SocioEconomic Status into policies impacting all beneficiaries and their providers.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
Implementation of P.L. 111-148 Patient Protection and Affordable Care Act; ESRD PPS and QIP rules for CY 2017; physician fee schedule rule for CY 2017; ESRD quality programs; ESRD Five Star initiative; Implementation of P.L. 113-93 Protecting Access to Medicare Act of 2014; HR 1130 Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; S 598 Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Implementation of Pub. L. No. 114-27 (H.R. 1295) Trade Preferences Extension Act of 2015; Senate Chronic Care Work Group; Letter to Issuers; Notice of Benefits and Payment Policy proposed rule; OCR antidiscrimination proposed and final rule; CMS Notice of Benefits and Payment Parameters final rule; Medicare MA and Part D Letter to Issues; coordinated care legislation
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, White House Office
2016 · third_quarter · Medicare/Medicaid
Implementation of P.L. 111-148 Patient Protection and Affordable Care Act; ESRD PPS and QIP rules; physician fee schedule rule; ESRD quality programs; ESRD Five Star initiative; Implementation of P.L. 113-93 Protecting Access to Medicare Act of 2014; H.R. 1130 and S. 598 Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Implementation of Pub. L. No. 114-27 (H.R. 1295) Trade Preferences Extension Act of 2015; OCR antidiscrimination proposed and final rule; CMS Notice of Benefits and Payment Parameters final rule, ESRD PPS and QIP Proposed Rule for CY 2017
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Medicare and Medicaid Services (CMS)
2016 · third_quarter · Medicare/Medicaid
Part D drug coverage and patient access issues and policy ESRD bundling and drug reimbursement issues HCPCS coding and reimbursement decisions Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Least costly alternative (LCA) policy Changes re: Medicare Part B and Average Sales Price Medicare secondary payor for ESRD services Extension of rebates on Medicare Part D drugs Performance measures for bone and mineral metabolism for ESRD program Implementation of American Taxpayer Relief Act of 2012 H.R. 1416, Cancer Patient Protection Act of 2015 21st Century Cures/Innovation initiatives, including H.R. 6, 21st Century Cures Act S. 506, To amend Part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes H.R. 696, To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes Medicaid drug rebate, drug coverage and patient access to therapies issues and policy S. 31, Medicare Prescription Drug Price Negotiation Act of 2015 H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 648, Medicare Formulary Improvement Act of 2015 H.R. 2, Medicare Access and CHIP Reauthorization Act of 2015 H.R.2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015 H.R. 5122, To prohibit further action on the proposed rule regarding testing of Medicare Part B Prescription Drug Models
Client expense: $270,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs, including those contained in S. 122, Safe and Affordable Drugs from Canada Act of 2015 Health technology assessment of orphan drugs Sequestration of FDA user fees H.R. 1376, Patient Choice Act of 2015 H.R. 790, Compassionate Freedom of Choice Act of 2015 H.R. 1600, Patients' Access to Treatments Act of 2015 21st Century Cures/Innovation initiatives including H.R. 6, 21st Century Cures Act and the Innovation for Healthier Americans Initiative, including the following: S. 2055, The Medical Countermeasures Innovation Act of 2015; S. 2512, Adding Zika Virus to the FDA Priority Review Voucher Program Act; S. 2030, The Advancing Targeted Therapies for Rare Diseases Act of 2015; S. 849, Advancing Research for Neurological Diseases Act of 2015; S. 2700, FDA and NIH Workfroces Authorities Modernization Act H.R. 909, Andrea Sloan CURE Act S. 1421 and H.R.971, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015 Implementation of the FDA Safety and Innovation Act (FDASIA) (Pub. L. 112-144) Regulation of innovative biological products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development S. 320, Medical Innovation Act H.R. 744, Medical Innovation Act S. 2615, Increasing Competition in Pharmaceuticals Act H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015 H.R. 1531 and S.1878, Advancing Hope Act of 2015 Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period Issues and policies related to biosimilars FDA guidance Issues and policies related to FDA oversight and management Issues and policies related to expanded access programs Issues and policies related to patient involvement with FDA decision making S. 289 and H.R. 2104, American Cures Act Legislation pertaining to FDA priority review vouchers, generally Legislation pertaining to the applicability of the ACA tax carve out for non-orphan drug designated drugs, generally, including H.R. 3678, Preserving Access to Orphan Drugs Act of 2015 H.R. 3618 and S. 1906, Orphan Drug Fairness Act Issues related to the value of prescription medicines, generally, and including S. 2023, Prescription Drug Affordability Act of 2015 Drug shortage issues Issues related to health care transparency S. 2055, Medical Countermeasure Innovation Act of 2016 H.R. 3299, Strengthening Public Health Emergency Response Act S. 2700, FDA and NIH Workforce Authorities Modernization Act S. 2713, Advancing Precision Medicine Act of 2016 S. 2745, Advancing NIH Strategic Planning and Representation in Medical Research Act S. 2742, Promoting Biomedical Research and Public Health for Patients Act S. 3239, H.R. 5858, The RACE for Children Act S. 2689, The REGROW Act S. 1878, Advancing Hope Act of 2016
Client expense: $270,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
Implementation of the Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); The Medicare Access and CHIP Reauthorization Act of 2015 (H.R. 1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The ERSD Choice Act (H.R. 5659); Issues related to ERSD Program; S. 598 and H.R. 1130, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Medicare Advantage; Senate Finance Committee Chronic Care Working Group; Integrated care legislation; Access to coverage in Health Insurance Marketplaces for ESRD; Implementation of Pub. L. 114-27, the Trade Preferences Extension Act of 2015; OCR anti-discrimination proposed and final rules; ERSD quality programs; ERSD payment rules.
Client expense: $230,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
Implementation of the Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); The Medicare Access and CHIP Reauthorization Act of 2015 (H.R. 1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The ERSD Choice Act (H.R. 5659); Issues related to ERSD Program; S. 598 and H.R. 1130, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Medicare Advantage; Senate Finance Committee Chronic Care Working Group; Integrated care legislation; Access to coverage in Health Insurance Marketplaces for ESRD; Implementation of Pub. L. 114-27, the Trade Preferences Extension Act of 2015; OCR anti-discrimination proposed and final rules; ERSD quality programs; ERSD payment rules.
Client expense: $230,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
Raise awareness with legislators about the barriers to and the importance of protecting access for home dialysis. The Chronic Kidney Disease Improvement in Research and Treatment Act is S.598 and H.R.1130 H.R.2948 Medicare Tele-health Parity Act of 2015 ESRD Choice Act HR 5659 CONNECT for Health Act S2484 Dialysis PATIENTS Act HR 5506
Client expense: $350,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
Issues related to End Stage Renal Disease (ESRD) program; S. 598/H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Senate Finance Committee's Chronic Care Working Group; H.R. 5659, ESRD Choice Act of 2016
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
Issues related to End Stage Renal Disease (ESRD); S. 598/H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act; Medicare Advantage; Senate Finance Committee's Chronic Care Working Group; Telehealth; H.R. 5659, ESRD Choice Act of 2016
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
2016 · third_quarter · Energy/Nuclear
S. 598 - Appliance Standards Improvement Act - Provisions on new product categories, one-watt standby power, new Energy Super Star designation S. 398 - Amendments to Energy Policy and Conservation Act - To improve energy efficiency of certain appliances & equipment S. 2012 - Energy Policy Modernization Act - To improve energy efficiency in buildings and appliances DOE TV energy use standards and energy consumption test procedures FTC Energy Guide labels; Environmental Marketing Claims/Green Guides EPA-DOE Energy Star specifications development (audio/DVD, TVs, computers, displays, set-top boxes, ventilation fans, luminaries, central air conditioners, residential refrigerators) DOE Appliance energy efficiency standards' development DOE Microwave energy use standards and test procedures (standby- and on-mode power) H.R. 4017 - Smart Energy Act - Provisions to create Federal loan program for energy efficiency upgrades in government, school, and hospital buildings DOE Energy conservation standards for commercial products' compressors DOE Energy conservation standards for split-type air conditioners DOE Energy conservation standards for computers DOE Energy use test procedures for TVs H.R. 2412 - New Energy for America Act - Tax credits for residential systems to enhance energy efficiency
Client expense: $150,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Energy, Dept of, Environmental Protection Agency (EPA), Federal Communications Commission (FCC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Natl Highway Traffic Safety Administration (NHTSA), Natl Telecommunications & Information Administration (NTIA), SENATE, Transportation, Dept of (DOT)
2016 · third_quarter · Health Issues
Healthcare reform In-home dialysis H.R. 1130/S.598 - The Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 FDA Reform Availability of medical products
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
H.R. 5506/ H.R. 5942/S. 3090 Dialysis PATIENT Demonstration Act of 2016 (All provisions) H.R. 5659 ESRD Choice Act of 2016 (All provisions) H.R. 270 Flexibility in Health IT Reporting Act (All provisions) S. 598 Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 (All provisions) H.R. 1130 Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 (All provisions) S. 776 Medication Therapy Management Empowerment Act of 2015 (All provisions) H.R. 244 MAC Transparency Act (All provisions) H.R. 2507 The Increasing Regulatory Fairness Act (All provisions) S. 2484 CONNECT for Health Act (All provisions) Comprehensive reforms to meaningful use; stage 3 meaningful use proposed rule CMS regulations related to the treatment of Medicare Part C and Part D CMS regulations pertaining to reimbursement rates for ESRD-related services CMS survey and certification of kidney dialysis centers CMS vascular care rate change proposal CMS/Medicare Advantage ESRD rate formulation
Client expense: $650,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
2016 · third_quarter · Medicare/Medicaid
H.R. 5506/S. 5090 Dialysis PATIENT Demonstration Act H.R. 5659 ESRD Choice Act of 2016 H.R. 270 Flexibility in Health IT Reporting Act (All provisions) S. 598 Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 (All provisions) H.R. 1130 Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 (All provisions) S. 776 Medication Therapy Management Empowerment Act of 2015 (All provisions) H.R. 244 MAC Transparency Act (All provisions) H.R. 2507 The Increasing Regulatory Fairness Act (All provisions) S. 2484 CONNECT for Health Act (All provisions) Comprehensive reforms to meaningful use; stage 3 meaningful use proposed rule CMS regulations pertaining to reimbursement rates for ESRD-related services CMS survey and certification of kidney dialysis centers CMS regulations related to the treatment of Medicare Part C and Part D CMS regulations pertaining to reimbursement rates for ESRD-related services CMS vascular care rate change proposal CMS/Medicare Advantage ESRD rate formulation
Client expense: $650,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
2016 · third_quarter · Health Issues
Implementation of Patient Protection and Affordable Care Act (including comments on inappropriate steering of individuals eligible for Medicare and Medicaid benefits to individual Marketplace plans) Initiatives to increase and facilitate organ transplantation,including S. 2584 and H.R. 4616, Living Donor Protection Act S. 598 and H.R. 1130, Chronic Kidney Disease Improvement in Research and Training Act Patient Access to drug therapies Initiatives to support early detection and management of Chronic Kidney Disease Insurance discrimination and Third Party Premium Assistance
Client expense: $65,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, Veterans Affairs, Dept of (VA), White House Office
2016 · third_quarter · Medical/Disease Research/Clinical Labs
The Chronic Kidney Disease Improvement in Research and Treatment Act S.598 H.R.1130.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
H.R.1130/S.598 - Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 - Issues related to giving ESRD patients greater choice in their Medicare coverage. H.R.5506/S. 3090 - Dialysis PATIENT Demonstration Act - legislation to create a comprehensive care model for individuals living with End Stage Renal Disease. Work on current and potential demonstration projects in Medicare to support better integration of care for ESRD patients with both CMS and Members of Congress. Issues focused on ESRD and Risk Adjustment for chronically ill patients and related work being conducted by the Senate Finance Committee. CMS policies related to Medicare Advantage with specific focus on the formula asserted for the Medicare Advantage Risk Adjustment factor and its impact on beneficiaries, plans and providers who serve Medicare Beneficiaries who live with multiple chronic conditions. Legislative and Administrative actions related to factoring in SocioEconomic Status into policies impacting all beneficiaries and their providers.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
H.R.1130/S.598 - Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 - Issues related to giving ESRD patients greater choice in their Medicare coverage. H.R.5506/S. 3090 - Dialysis PATIENT Demonstration Act - legislation to create a comprehensive care model for individuals living with End Stage Renal Disease. Work on current and potential demonstration projects in Medicare to support better integration of care for ESRD patients with both CMS and Members of Congress. Issues focused on ESRD and Risk Adjustment for chronically ill patients and related work being conducted by the Senate Finance Committee. Legislative and Administrative actions related to factoring in Socio Economic Status into policies impacting all beneficiaries and their providers.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
Urge Congress to open Medicare Advantage to dialysis patients (HR 5659); Support ESRD care coordination legislation - the Dialysis PATIENTS Act (HR 5506/S 3090); Encourage support for to improve kidney disease research and treatment (HR 1130/S 598); Protect Medicare funding for dialysis patients; Improve access to home dialysis treatment; and Ensure ESRD patients retain access to commercial insurance.
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
Discussed legislation concerning care delivery models for Medicare beneficiaries with kidney disease (including HR 5506/S 3090) Supported legislation to permit patients with ESRD enrolling in Medicare Advantage Plans (H.R. 5659) Discussed transplantation policy in general Implementation of 2015 TAA/TPA legislation related to AKI care Supported HR1130/S598 (comprehensive kidney care legislation)
Client expense: $20,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, Veterans Affairs, Dept of (VA), White House Office
2016 · second_quarter · Medicare/Medicaid
Part D drug coverage and patient access issues and policy ESRD bundling and drug reimbursement issues HCPCS coding and reimbursement decisions Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Least costly alternative (LCA) policy Changes re: Medicare Part B and Average Sales Price Medicare secondary payor for ESRD services Extension of rebates on Medicare Part D drugs Performance measures for bone and mineral metabolism for ESRD program Implementation of American Taxpayer Relief Act of 2012 H.R. 1416, Cancer Patient Protection Act of 2015 21st Century Cures/Innovation initiatives, including H.R. 6, 21st Century Cures Act S. 506, To amend Part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes H.R. 696, To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes Medicaid drug rebate, drug coverage and patient access to therapies issues and policy S. 31, Medicare Prescription Drug Price Negotiation Act of 2015 H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 648, Medicare Formulary Improvement Act of 2015 H.R. 2, Medicare Access and CHIP Reauthorization Act of 2015 H.R.2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015 H.R. 5122, To prohibit further action on the proposed rule regarding testing of Medicare Part B Prescription Drug Models
Client expense: $280,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Health Issues
Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs, including those contained in S. 122, Safe and Affordable Drugs from Canada Act of 2015 Health technology assessment of orphan drugs Sequestration of FDA user fees H.R. 1376, Patient Choice Act of 2015 H.R. 790, Compassionate Freedom of Choice Act of 2015 H.R. 1600, Patients' Access to Treatments Act of 2015 21st Century Cures/Innovation initiatives including H.R. 6, 21st Century Cures Act and the Innovation for Healthier Americans Initiative, including the following: S. 2055, The Medical Countermeasures Innovation Act of 2015; S. 2512, Adding Zika Virus to the FDA Priority Review Voucher Program Act; S. 2030, The Advancing Targeted Therapies for Rare Diseases Act of 2015; S. 849, Advancing Research for Neurological Diseases Act of 2015; S. 2700, FDA and NIH Workfroces Authorities Modernization Act H.R. 909, Andrea Sloan CURE Act S. 1421 and H.R.971, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015 Implementation of the FDA Safety and Innovation Act (FDASIA) (Pub. L. 112-144) Regulation of innovative biological products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development S. 320, Medical Innovation Act H.R. 744, Medical Innovation Act S. 2615, Increasing Competition in Pharmaceuticals Act H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015 H.R. 1531 and S.1878, Advancing Hope Act of 2015 Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period Issues and policies related to biosimilars FDA guidance Issues and policies related to FDA oversight and management Issues and policies related to expanded access programs Issues and policies related to patient involvement with FDA decision making S. 289 and H.R. 2104, American Cures Act Legislation pertaining to FDA priority review vouchers, generally Legislation pertaining to the applicability of the ACA tax carve out for non-orphan drug designated drugs, generally, including H.R. 3678, Preserving Access to Orphan Drugs Act of 2015 H.R. 3618 and S. 1906, Orphan Drug Fairness Act Issues related to the value of prescription medicines, generally, and including S. 2023, Prescription Drug Affordability Act of 2015 Drug shortage issues Issues related to health care transparency S. 2055, Medical Countermeasure Innovation Act of 2016 H.R. 3299, Strengthening Public Health Emergency Response Act S. 2700, FDA and NIH Workforce Authorities Modernization Act S. 2713, Advancing Precision Medicine Act of 2016 S. 2745, Advancing NIH Strategic Planning and Representation in Medical Research Act S. 2742, Promoting Biomedical Research and Public Health for Patients Act S. 3239, H.R. 5858, The RACE for Children Act S. 2689, The REGROW Act
Client expense: $280,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE